Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect wa...

Full description

Saved in:
Bibliographic Details
Published in:Open forum infectious diseases Vol. 2; no. 4; p. ofv175
Main Authors: Grard, Soazic, Catho, Gaud, Valour, Florent, Bouaziz, Anissa, Perpoint, Thomas, Braun, Evelyne, Biron, François, Miailhes, Patrick, Ferry, Tristan, Chidiac, Christian, Souquet, Pierre-Jean, Couraud, Sébastien, Lina, Gérard, Goutelle, Sylvain, Veziris, Nicolas, Dumitrescu, Oana, Ader, Florence
Format: Journal Article
Language:English
Published: United States Oxford University Press 01.12.2015
Subjects:
Bacteriology
Brief Reports
Immunology
Life Sciences
Microbiology and Parasitology
Virology
neuropathy
ethionamide
linezolid
multidrug-resistant tuberculosis
ISSN:2328-8957, 2328-8957
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Linezolid (LNZ), a group 5 antituberculous drug (unclear efficacy), was used in the starter regimens of 23 adults with multidrug-resistant tuberculosis. The LNZ-containing regimens were effective in achieving culture conversions and relapse-free outcomes. The most frequent LNZ-related side effect was neuropathy. We propose that LNZ should be reclassified among bactericidal second-line drugs.
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Report-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMCID: PMC4690547
O. D. and F. A. contributed equally to this work.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofv175